The Role of Intestinal Fungi and Its Metabolites in Chronic Liver Diseases

키워드

참고문헌 (49)

1. Sekirov I, "Gut microbiota in health and disease", Physiol Rev, 90, pp.859~904 (2010)
2. Carter BA, "Intestinal failure-associated liver disease : management and treatment strategies past, present, and future", Semin Liver Dis, 27, pp.251~258 (2007)
3. Romani L, "Immunity to fungal infections", Nat Rev Immunol, 11, pp.275~288 (2011)
4. Dollive S, "Fungi of the murine gut : episodic variation and proliferation during antibiotic treatment", PLoS One, 8, pp.e71806~ (2013)
5. Schulze J, "Yeasts in the gut : from commensals to infectious agents", Dtsch Arztebl Int, 106, pp.837~842 (2009)
6. Qin J, "A human gut microbial gene catalogue established by metagenomic sequencing", Nature, 464, pp.59~65 (2010)
7. Ott SJ, "Fungi and inflammatory bowel diseases : alterations of composition and diversity", Scand J Gastroenterol, 43, pp.831~841 (2008)
8. Hoffmann C, "Archaea and fungi of the human gut microbiome : correlations with diet and bacterial residents", PLoS One, 8, pp.e66019~ (2013)
9. Suhr MJ, "The human gut mycobiome : pitfalls and potentials : a mycologist’s perspective", Mycologia, 107, pp.1057~1073 (2015)
10. Mar Rodríguez M, "Obesity changes the human gut mycobiome", Sci Rep, 5, pp.14600~ (2015)
11. Wang ZK, "Review article : fungal microbiota and digestive diseases", Aliment Pharmacol Ther, 39, pp.751~766 (2014)
12. Scupham AJ, "Abundant and diverse fungal microbiota in the murine intestine", Appl Environ Microbiol, 72, pp.793~801 (2006)
13. Nash AK, "The gut mycobiome of the Human Microbiome Project healthy cohort", Microbiome, 5, pp.153~ (2017)
14. Voican CS, "Mechanisms of the inflammatory reaction implicated in alcoholic hepatitis : 2011 update", Clin Res Hepatol Gastroenterol, 35, pp.465~474 (2011)
15. Szabo G, "Gut-liver axis in alcoholic liver disease", Gastroenterology, 148, pp.30~36 (2015)
16. Schnabl B, "Interactions between the intestinal microbiome and liver diseases", Gastroenterology, 146, pp.1513~1524 (2014)
17. Chen P, "Dysbiosis-induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice", Hepatology, 61, pp.883~894 (2015)
18. Yang AM, "Intestinal fungi contribute to development of alcoholic liver disease", J Clin Invest, 127, pp.2829~2841 (2017)
19. Fatima N, "Epicoccum SP., an emerging source of unique bioactive metabolites", Acta Pol Pharm, 73, pp.13~21 (2016)
20. Braga RM, "The biotechnological potential of Epicoccum spp. : diversity of secondary metabolites", Crit Rev Microbiol, 44, pp.759~778 (2018)
21. Kelesidis T, "Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders", Therap Adv Gastroenterol, 5, pp.111~125 (2012)
22. Everard A, "Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db", db mice, 2014, pp.5, e01011~e01014
23. Liu YT, "Protective effect of Saccharomyces boulardii against intestinal mucosal barrier injury in rats with nonalcoholic fatty liver disease", Zhonghua Gan Zang Bing Za Zhi, 24, pp.921~926 (2016)
24. Heisel T, "High-fat diet changes fungal microbiomes and interkingdom relationships in the murine gut", mSphere, 2, pp.e00351~e00417 (2017)
25. El Bialy SA, "Current progress in antifibrotics", Curr Med Chem, 18, pp.3082~3092 (2011)
26. Bajaj JS, "Fungal dysbiosis in cirrhosis", Gut, 67, pp.1146~1154 (2018)
27. Bajaj JS, "Second infections independently increase mortality in hospitalized patients with cirrhosis : the North American consortium for the study of end-stage liver disease(NACSELD)experience", Hepatology, 56, pp.2328~2335 (2012)
28. Lahmer T, "Fungal"colonisation"is associated with increased mortality in medical intensive care unit patients with liver cirrhosis", Mycopathologia, 179, pp.63~71 (2015)
29. Chen Y, "Correlation between gastrointestinal fungi and varying degrees of chronic hepatitis B virus infection", Diagn Microbiol Infect Dis, 70, pp.492~498 (2011)
30. Brown KS, "Mannan binding lectin and viral hepatitis", Immunol Lett, 108, pp.34~44 (2007)
31. Knoke M, "Gastrointestinal microecology of humans and Candida", Mycoses, 42(Suppl 1), pp.30~34 (1999)
32. Lee DS, "PTP1B inhibitory and anti-inflammatory effects of secondary metabolites isolated from the marine-derived fungus Penicillium sp. JF-55", Mar Drugs, 11, pp.1409~1426 (2013)
33. Sougioultzis S, "Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression", Biochem Biophys Res Commun, 343, pp.69~76 (2006)
34. Okiyama W, "Polyenephosphatidylcholine prevents alcoholic liver disease in PPARalpha-null mice through attenuation of increases in oxidative stress", J Hepatol, 50, pp.1236~1246 (2009)
35. Roth CL, "Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Toll-like receptor activation", Hepatology, 55, pp.1103~1111 (2012)
36. Czerucka D, "Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells", Infect Immun, 68, pp.5998~6004 (2000)
37. Schneider SM, "Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition", World J Gastroenterol, 11, pp.6165~6169 (2005)
38. Ye J, "Butyrate protects mice against methionine-choline-deficient diet-induced non-alcoholic steatohepatitis by improving gut barrier function, attenuating inflammation and reducing endotoxin levels", Front Microbiol, 9, pp.1967~ (2018)
39. Castagliuolo I, "Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum", Infect Immun, 64, pp.5225~5232 (1996)
40. Buts JP, "Saccharomyces boulardii produces in rat small intestine a novel protein phosphatase that inhibits Escherichia coli endotoxin by dephosphorylation", Pediatr Res, 60, pp.24~29 (2006)
41. Joo JH, "Molecular mechanisms involved in farnesol-induced apoptosis", Cancer Lett, 287, pp.123~135 (2010)
42. Rossignol T, "Transcriptional response of Candida parapsilosis following exposure to farnesol", Antimicrob Agents Chemother, 51, pp.2304~2312 (2007)
43. Liu P, "Farnesol induces apoptosis and oxidative stress in the fungal pathogen Penicillium expansum", Mycologia, 102, pp.311~318 (2010)
44. Machida K, "Farnesol-induced generation of reactive oxygen species dependent on mitochondrial transmembrane potential hyperpolarization mediated by F(0)F(1)-ATPase in yeast", FEBS Lett, 462, pp.108~112 (1999)
45. Machida K, "Farnesol-induced generation of reactive oxygen species via indirect inhibition of the mitochondrial electron transport chain in the yeast Saccharomyces cerevisiae", J Bacteriol, 180, pp.4460~4465 (1998)
46. Davis-Hanna A, "Farnesol and dodecanol effects on the Candida albicans Ras1-cAMP signalling pathway and the regulation of morphogenesis", Mol Microbiol, 67, pp.47~62 (2008)
47. Lorek J, "Influence of farnesol on the morphogenesis of Aspergillus niger", J Basic Microbiol, 48, pp.99~103 (2008)
48. Pant A, "Farnesol induces fatty acid oxidation and decreases triglyceride accumulation in steatotic HepaRG cells", Toxicol Appl Pharmacol, 365, pp.61~70 (2019)
49. Zheng Z, "Altenusin, a nonsteroidal microbial metabolite, attenuates nonalcoholic fatty liver disease by activating the farnesoid X receptor", Mol Pharmacol, 92, pp.425~436 (2017)

관련 논문AI추천